Vera Therapeutics (VERA) to Release Earnings on Thursday

Vera Therapeutics (NASDAQ:VERA) is projected to post its Q3 2025 results before the market opens on Thursday, November 6th. Analysts expect Vera Therapeutics to post earnings of ($1.20) per share for the quarter. Individuals can check the company’s upcoming Q3 2025 earningsummary page for the latest details on the call scheduled for Friday, November 7, 2025 at 12:30 PM ET.

Vera Therapeutics (NASDAQ:VERA) last issued its quarterly earnings data on Tuesday, August 5th. The company reported ($1.20) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.38). During the same period in the prior year, the company posted ($0.62) earnings per share. On average, analysts expect Vera Therapeutics to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Vera Therapeutics Price Performance

Shares of VERA opened at $29.36 on Thursday. Vera Therapeutics has a 1 year low of $18.53 and a 1 year high of $51.61. The company has a debt-to-equity ratio of 0.16, a current ratio of 17.03 and a quick ratio of 17.03. The company has a market capitalization of $1.87 billion, a price-to-earnings ratio of -8.20 and a beta of 1.23. The business has a 50-day moving average of $26.79 and a 200-day moving average of $23.91.

Institutional Investors Weigh In On Vera Therapeutics

A number of hedge funds have recently added to or reduced their stakes in VERA. Vestal Point Capital LP grew its stake in Vera Therapeutics by 24.0% in the second quarter. Vestal Point Capital LP now owns 3,100,000 shares of the company’s stock valued at $73,036,000 after acquiring an additional 600,000 shares during the period. Hudson Bay Capital Management LP acquired a new stake in Vera Therapeutics in the second quarter valued at approximately $7,044,000. JPMorgan Chase & Co. grew its stake in Vera Therapeutics by 550.5% in the second quarter. JPMorgan Chase & Co. now owns 310,547 shares of the company’s stock valued at $7,316,000 after acquiring an additional 262,805 shares during the period. Bank of America Corp DE grew its stake in Vera Therapeutics by 73.7% in the second quarter. Bank of America Corp DE now owns 394,280 shares of the company’s stock valued at $9,289,000 after acquiring an additional 167,264 shares during the period. Finally, MPM Bioimpact LLC grew its stake in Vera Therapeutics by 35.4% in the second quarter. MPM Bioimpact LLC now owns 563,075 shares of the company’s stock valued at $13,266,000 after acquiring an additional 147,356 shares during the period. Institutional investors and hedge funds own 99.21% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on the company. Wolfe Research restated a “peer perform” rating on shares of Vera Therapeutics in a research report on Monday, August 4th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Vera Therapeutics in a report on Thursday, September 18th. Bank of America started coverage on Vera Therapeutics in a report on Thursday, October 16th. They issued a “buy” rating and a $48.00 target price for the company. JPMorgan Chase & Co. lowered their target price on Vera Therapeutics from $56.00 to $53.00 and set an “overweight” rating for the company in a report on Thursday, August 7th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Vera Therapeutics in a report on Wednesday, October 8th. Eight equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Vera Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $61.50.

Vera Therapeutics Company Profile

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.